Development of site profiles for dose reconstruction used in worker compensation claims.

Health Phys

Dade Moeller & Associates Inc., 2750 Prosperity Avenue, Suite 500, Fairfax, VA 22031, USA.

Published: July 2008

For the purpose of dose reconstruction, personal dosimeter data and measured intakes through bioassay analysis (i.e., in-vivo and in-vitro measurements) should be used whenever possible and given precedence over area monitoring data, survey data, or source term data. However, this is not always possible. A worker's exposure record may be incomplete or missing, or, based on directives and guidelines at the time, a worker may not have been monitored during his or her time of employment. In an effort to recognize, analyze, and incorporate all possible considerations of potential exposures, the National Institute for Occupational Safety and Health Radiation Dose Reconstruction Program developed "site profiles" for all of the major U.S. Department of Energy sites and Atomic Weapons Employer sites. Site profiles are technical documents that (1) provide a brief, general overview of the site; (2) identify the facilities on site with a brief description of the processes and radionuclides used in these processes; (3) contain detailed information on the historical detection limits for film, thermoluminescent dosimeter, and bioassay measurements that are used by the dose reconstructor to interpret a worker's available monitoring records; and (4) provide important supporting information for the dose reconstructor to use if the monitoring data are inadequate or unavailable. When a complete set of monitoring data for an individual is unavailable, it is the parameters in the site profile that are of the most use to the dose reconstructor. These parameters include facility monitoring data (by radionuclide, mechanism of intake, year of exposure, location within a facility); occupational medical x rays and techniques used; environmental measurements (by area on site, radiation type, energy range); minimum detectable activities of the types and kinds of instruments used to detect the different radionuclides; specific source terms (quantities of material and their molecular form) within each facility or process; and specifics of the overall dosimetry programs as they evolved over time. An additional benefit of having a site profile for a site is that it promotes consistency among the numerous health physicists that are working on the project. Resources used in the development of site profiles include technical basis documents for external and internal dosimetry programs, facility descriptions, environmental reports, safety analysis reports, input from past and present site workers, and other reports that have been written to describe the workplace environments within the facilities.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.HP.0000300755.20134.54DOI Listing

Publication Analysis

Top Keywords

monitoring data
16
site profiles
12
dose reconstruction
12
dose reconstructor
12
site
9
development site
8
site profile
8
dosimetry programs
8
data
7
dose
6

Similar Publications

Objectives: We assessed HIV-1 drug resistance profiles among people living with HIV (PLWH) with detectable viral load (VL) and on dolutegravir-based antiretroviral therapy (ART) in Botswana.

Methods: The study utilised available 100 residual HIV-1 VL samples from unique PLWH in Francistown who had viraemia at-least 6 months after initiating ART in Botswana's national ART program from November 2023 to January 2024. Viraemia was categorized as low-level viraemia (LLV) (VL: 200-999 copies/mL) or virologic failure (VF) (VL ≥1000 copies/mL).

View Article and Find Full Text PDF

Technological advances in clinical individualized medication for cancer therapy: from genes to whole organism.

Per Med

January 2025

Department of Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Efforts have been made to leverage technology to accurately identify tumor characteristics and predict how each cancer patient may respond to medications. This involves collecting data from various sources such as genomic data, histological information, functional drug profiling, and drug metabolism using techniques like polymerase chain reaction, sanger sequencing, next-generation sequencing, fluorescence in situ hybridization, immunohistochemistry staining, patient-derived tumor xenograft models, patient-derived organoid models, and therapeutic drug monitoring. The utilization of diverse detection technologies in clinical practice has made "individualized treatment" possible, but the desired level of accuracy has not been fully attained yet.

View Article and Find Full Text PDF

Exploring esophagogastric junction morphology and contractile integral: implications for refractory gastroesophageal reflux disease pathophysiology.

Scand J Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Xiamen Branch, Xiamen, China.

Background: Evaluate the clinical significance of esophagogastric junction (EGJ) morphology and esophagogastric junction contractile integral (EGJ-CI) in refractory gastroesophageal reflux disease (RGERD) patients.

Methods: From June 2021 to June 2023, 144 RGERD patients underwent comprehensive evaluation, recording symptom scores, demographic data. GERD classification (NERD or RE, A-D) was based on endoscopic findings.

View Article and Find Full Text PDF

Aims: According to the 2023 International Consensus, glucose metrics derived from two-week-long continuous glucose monitoring (CGM) can be extrapolated up to 90 days before. However, no studies have focused on adults with type 1 diabetes (T1D) on multiple daily injections (MDIs) and with second-generation intermittently scanned CGM (isCGM) sensors in a real-world setting.

Methods: This real-world, retrospective study included 539 90-day isCGM data from 367 adults with T1D on MDI therapy.

View Article and Find Full Text PDF

Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.

Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!